[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351193-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351193-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","notch3-attenuates-cytotoxicity-via-rbpj-dependent-pvr-upregulation-to-influence-immunotherapy-outcomes-in-colorectal-cancer","NOTCH3 attenuates cytotoxicity via RBPJ-dependent PVR upregulation to influence immunotherapy outcomes in colorectal cancer","","NOTCH3 is identified as a frequently altered driver linked to worse outcomes and an immunosuppressive microenvironment in colorectal cancer. Multi-omics analyses integrate TCGA alterations with immune infiltration and scRNA-seq to connect NOTCH3 activity to checkpoint signaling. Mechanistically, NOTCH3 transcriptionally increases PVR through RBPJ binding, which restrains CD8+ T cell cytotoxicity and strengthens PVR-TIGIT cancer–immune interactions. NOTCH3 depletion synergizes with anti-PD-L1 therapy, and clinical cohorts show mutation or low expression predicts improved immunotherapy survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/notch3-attenuates-cytotoxicity-via-rbpj-dependent-pvr-upregulation-to-influence-immunotherapy-outcomes-in-colorectal-cancer/351193/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/notch3-attenuates-cytotoxicity-via-rbpj-dependent-pvr-upregulation-to-influence-immunotherapy-outcomes-in-colorectal-cancer/351193.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main role of NOTCH3 in colorectal cancer in this study?","Question",{"text":63,"@type":64},"NOTCH3 promotes an immunosuppressive tumor microenvironment and correlates with poor survival in colorectal cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does NOTCH3 regulate PVR according to the study’s mechanism?",{"text":68,"@type":64},"NOTCH3 transcriptionally upregulates the immune checkpoint molecule PVR by binding the transcription factor RBPJ.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic implication is tested and supported by the results?",{"text":72,"@type":64},"In models and cohorts, NOTCH3 depletion enhances the efficacy of anti-PD-L1 therapy by inhibiting tumor growth and increasing CD8+ T cell infiltration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351193,1790676779,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","TYPE Original Research PUBLISHED 23 February 2026 DOI 10.3389/fimmu.2026.1741261  \nOPEN ACCESS  \nEDITED BY  \nDi Du,  \nExxonMobil Research and Engineering, United States  \nREVIEWED BY  \nDavid H. Mauki, Sichuan University, China He Ren,  \nShanghai University of Medicine and Health Sciences, China  \nLei Liu,  \nFudan University, China  \n*CORRESPONDENCE  \nYing Liu  \n [liuyinghch@126.com](liuyinghch@126.com)[ ](liuyinghch@126.com)Fei Ma  \n [mafeizzu@outlook.com](mafeizzu@outlook.com)  \n†These authors have contributed equally to this work  \nRECEIVED 07 November 2025  \nREVISED 09 January 2026  \nACCEPTED 14 January 2026  \nPUBLISHED 23 February 2026  \nCITATION  \nMa Q, Xu S, Ma N, Li K, Liu Y and Ma F (2026) NOTCH3 attenuates cytotoxicity via RBPJ  \ndependent PVR upregulation to inﬂuence immunotherapy outcomesin colorectal cancer.  \nFront. Immunol. 17:1741261 .  \ndoi: 10.3389/fimmu.2026.1741261  \nCOPYRIGHT  \n© 2026 Ma, Xu, Ma, Li, Liu and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nNOTCH3 attenuates cytotoxicity via RBPJ-dependent PVRupregulation to inﬂuence immunotherapy outcomesin colorectal cancer  \nQi Ma 1†, Shuning Xu 2†, Ning Ma 3, Ke Li 2, Ying Liu 2* and Fei Ma 1*  \n1 Department of General Surgery, The Afﬁliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China, 2 Department of Medical Oncology, The Afﬁliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China, 3 Department of Oncology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, Henan, China  \nIntroduction: This study aimed to elucidate the function of NOTCH3 in pan-cancer and CRC progression, its impact on the tumor immune microenvironment, and its value as a therapeutic target and predictive biomarker. Methods: We performed a multi-omics analysis of NOTCH3 alterations (expression, mutation, copy number variation, methylation) using data from The Cancer Genome Atlas (TCGA) . Immune cell inﬁltration was assessed using multiple algorithms and single-cell RNA sequencing (scRNA-seq) data from CRC patients. In vitro functional experiments, including co-immunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assays, and CD8+ T cell cytotoxicity co-cultures, were conducted in CRC cell line . An immunecompetent mouse xenograft model was used to evaluate the efﬁcacy of antiNOTCH3 in combination with anti-PD-L1 therapy. Clinical validation was performed using independent immunotherapy-treated cohorts from the MSKCC database and our institutional cohort (102 patients) via immunohistochemistry and survival analysis.  \nResults: NOTCH3 is frequently altered across multiple cancers. In CRC, high NOTCH3 expression correlated with poor survival and fostered an immunosuppressive microenvironment. Mechanistically, NOTCH3 transcriptionally upregulates the immune checkpoint molecule PVR by binding to the transcription factor RBPJ; this process is abrogated by NOTCH3 mutations (e.g., R1669H) . NOTCH3-mediated PVR upregulation suppressed CD8+ T cell cytotoxicity. scRNA-seq analysis revealed enhanced PVR-TIGIT interactions between cancer and immune cells in NOTCH3-high tumors. In vivo, NOTCH3 depletion synergized with anti-PD-L1 therapy to inhibit tumor growth and increase CD8+ T cell inﬁltration. Clinically, NOTCH3 mutation or low expression independently predicted improved survival in immunotherapy-treated CRC and pan-cancer cohorts.  \nConclusion: NOTCH3 is a pivotal regulator of immune evasion in CRC via the RBPJ-PVR axis.  \nKEYWORDS  \nCRC, immunotherapy","cbCaifIXl9izAhmP","https://ap.wps.com/l/cbCaifIXl9izAhmP","pdf",15030725,16,"English","# Introduction\n# Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What is the main role of NOTCH3 in colorectal cancer in this study?\",\"answer\":\"NOTCH3 promotes an immunosuppressive tumor microenvironment and correlates with poor survival in colorectal cancer.\"},{\"question\":\"How does NOTCH3 regulate PVR according to the study’s mechanism?\",\"answer\":\"NOTCH3 transcriptionally upregulates the immune checkpoint molecule PVR by binding the transcription factor RBPJ.\"},{\"question\":\"What therapeutic implication is tested and supported by the results?\",\"answer\":\"In models and cohorts, NOTCH3 depletion enhances the efficacy of anti-PD-L1 therapy by inhibiting tumor growth and increasing CD8+ T cell infiltration.\"}]","NOTCH3 attenuates cytotoxicity via RBPJ-dependent PVR upregulation to influence immunotherapy outcomes in colorectal cancer | PDF",1790093016,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c554b4dd5023700569826ef3068718b3.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/928021b9a01cbf44af0f59d336e1c22c.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9122183bf637b47cd0f8acb967abdc56.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d56a9329f39ecf8049125867e668a50.webp",980,1385]